National Health (Transitional Electronic National Residential Medication Chart) Special Arrangement 2025

The instrument introduces a concise set of central concepts that determine eligibility to participate in the special arrangement and the mechanics of e‑prescribing and claiming.

• Electronic medication chart and electronic medication order. The core prescribing unit is an electronic medication order inside an electronic medication chart. An electronic medication chart must contain all the standard fields set out in Schedule 1 to the National Health (Pharmaceutical Benefits) National Residential Medication Charts Approval Instrument 2025, as it exists on 1 November 2025 (s4 definition of electronic medication chart). The instrument expressly cross‑references the Approval Instrument; it does not reproduce the fields in full. A prescriber must create the electronic medication order within that chart and electronically approve it (s8(1), s8(4), s8(6)). The electronic medication order must include any authority approval number or streamlined authority code required for the prescription (s8(5)).

• Electronic medication chart system. That chart must be created and managed within an electronic medication chart system owned and operated by a software vendor, and the instrument defines three system attributes: used for prescribing/recording administration in approved residential care homes; accessible by approved suppliers for viewing and annotating charts; and the system must not allow charts or orders created using the system to be sent to the national prescription delivery service (s4 definition of electronic medication chart system). The third attribute is a functional constraint that restricts the route of electronic transmission.

• Transitional conformance and register. A transitional conformant electronic medication chart system is one listed on the Transitional eNRMC Conformance Register maintained by the Australian Digital Health Agency, as that register exists on 1 October 2025 (s4 definitions). The instrument therefore uses a fixed snapshot of a register for conformity, not a rolling or dynamically updated test inside the instrument.

• Scope of beneficiaries and supplies. The arrangement applies only to pharmaceutical benefits generally available under Part VII, except where a pharmaceutical benefit is exclusively covered by a different special arrangement or other determinations (s6). The prescriber and supplier coverage is limited to persons receiving residential care at an approved residential care home; the instrument also contains a bridging provision so that references include persons receiving residential care under the prior Aged Care Act definitions for prescriptions between 1 November 2025 and registration of a named Amendment (s8(2)(a), s14).

• Modifications to Regulations and Rules. The instrument modifies how certain Regulation provisions apply to electronic medication orders. For example, paragraphs 41(2)(c) and 41(2)(g) of the Regulations do not apply to the creation of an electronic medication order within an electronic medication chart (s8(3)). It also treats an electronic medication order as a medication chart prescription for purposes of the Regulations (other than s61) and the Rules (s8(6), s7(2)). For supply, sections 45, 47 and 51 of the Regulations apply subject to the instrument’s specified modifications, including how verification of supply is recorded (s9(2)).

• Claims and record keeping. Approved suppliers may make claims for payment under the Rules modified by the instrument (s10(1)). Suppliers must prepare and retain an electronic pharmacy record for each supply based on an electronic medication order, for at least two years after supply, and the record must include all information required by Schedule 1 to the Rules for a CTS claim (s10(5)-(6)). The Chief Executive Medicare can require submission of copies of electronic medication orders or electronic pharmacy records in writing; such notices may apply to one or more orders or records (s10(4), (7)-(8)).

• Limited coding concession for Fred IT Group software. The instrument creates a narrowly described claim coding outcome: where a claim relates to supplies using software made available by Fred IT Group Pty Ltd (ABN provided) and the supply either required Chief Executive Medicare authorisation under a specified instrument or concerns a drug referred to in Schedule 8 of the Poisons Standard, the Patient Category details for a patient in the Residential aged care facility patient (medication chart prescription) category are 0 (zero) for item 25 of the Rules’ Schedule 1 table (s10(2)-(3)). The instrument therefore ties a claim coding treatment to a named supplier’s software in specified circumstances.

• Transitional continuity. The instrument preserves the continued operation of section 9 and 10 of the former Special Arrangement (the 2018 trial instrument) for supplies and claims based on transitional prescriptions made before the transition time, despite repeal of the former Special Arrangement (ss11-13). It also bridges differences in aged care definitions for prescriptions in a discrete interregnum between 1 November 2025 and registration of an Amendment Special Arrangement (s14).

These concepts set the boundaries of who can prescribe and how, how suppliers must verify and record supply, which software is acceptable, and how claims are to be coded and supported. The instrument places operational control in three discrete hands: the software vendor (owner/operator of the chart system), the Australian Digital Health Agency (by maintenance of the Transitional eNRMC Conformance Register), and Chief Executive Medicare (by written notices requiring submission of orders or records). The following sections address affected parties, duties and rights, enforcement arrangements, legal cross‑references, historical record, litigation record in the source, practical traps and compliance steps.

The instrument creates and concentrates obligations across several defined groups and creates indirect effects for related market participants.

• PBS prescribers. A PBS prescriber may only make a prescription under this Special Arrangement by creating an electronic medication order within an approved electronic medication chart system and must electronically approve the prescription (s8(1), s8(4), s8(6)). They are limited to prescribing only for persons receiving residential care at an approved residential care home, while PBS prescribers remain subject to state and territory restrictions on prescribing and dispensing Schedule 8 drugs (s8(2), s8(3) note).

• Approved suppliers (pharmacies). Approved suppliers may supply a pharmaceutical benefit under the Special Arrangement only where the prescription was created using a transitional conformant system and was made available to the supplier before supply (s9(1)). Suppliers are required to verify supply in the electronic medication order as if section 45 of the Regulations required such verification, and to include the date of supply in the electronic order (s9(2)(b)(i)). Approved suppliers also must prepare and retain electronic pharmacy records for at least two years and include the information required by Schedule 1 to the Rules for CTS claims (s10(5)-(6)). Chief Executive Medicare may require suppliers to submit copies of electronic medication orders or pharmacy records (s10(4), (7)).

• Software vendors and system owners/operators. The instrument specifically governs electronic medication chart systems; a system must be transitional conformant by being listed on the Transitional eNRMC Conformance Register as at 1 October 2025 in order to be used for prescriptions under the arrangement (s4 definitions). The system must be owned and operated by a software vendor, be accessible by approved suppliers for viewing and annotating charts, and must not allow charts/orders to be sent to the national prescription delivery service (s4). These requirements directly affect vendors’ product design, interoperability features and market eligibility.

• Approved residential care homes and residential care services. The arrangement applies only to people receiving residential care in approved residential care homes (s8(2)(a), s4 definition of residential care). Section 14 creates a temporary expansion for relevant prescriptions and supplies written between 1 November 2025 and registration of a named Amendment Special Arrangement, treating persons under the old Aged Care Act definitions as within scope during that interregnum (s14).

• The Australian Digital Health Agency. The instrument uses the Transitional eNRMC Conformance Register maintained by the Agency as the gatekeeper for transitional conformance (s4). The register’s content as of 1 October 2025 is decisive for eligibility.

• Chief Executive Medicare and the Department administering the Human Services (Centrelink) Act 1997. Chief Executive Medicare receives a role in authorising particular prescriptions in relation to clause 1 item 25 (s10(3)(a) cross‑reference), and has the power to notify suppliers in writing to submit copies of electronic medication orders or records to the Department administered by the Minister who administers the Human Services (Centrelink) Act 1997 (s10(4), (7)).

• Named private entity: Fred IT Group Pty Ltd. The instrument names Fred IT Group and its ABN when specifying a claim coding effect for supplies made using its software in particular circumstances (s10(3)). That creates a direct, instrument‑level differential outcome for claims processed via that vendor’s software.

Indirectly affected parties include state and territory regulators for controlled drugs (Schedule 8), pharmacy software vendors who rely on the national prescription delivery service to transmit e‑prescriptions (those systems will be excluded for these eNRMC prescriptions by design), aged care operators who must adopt or integrate with transitional conformant chart systems, and third‑party integrators who support supply workflows or claims submission. The instrument also affects claims administrators and compliance teams because of the two‑year retention requirement for electronic pharmacy records and the Chief Executive Medicare notice power to require document submission (s10(5)-(8)).

Cost concentration and distribution. The instrument concentrates initial compliance costs on software vendors (to meet conformance and register listing requirements, and to disable or omit transmission to the national prescription delivery service), on approved suppliers (to ensure access to the vendor system, to verify supply inside the electronic medication order, and to store and produce electronic pharmacy records), and on approved residential care homes (to provide the onsite systems and workflows). PBS prescribers face system use obligations and identity/authentication responsibilities when electronically approving orders. The instrument confers a small, explicit regulatory advantage to users of the named Fred IT Group software in the narrow claim coding outcome described in s10(3), which is relevant to approved suppliers who use that software for feeds or claims for certain items.

Geographical and procedural limits. The arrangement is limited to Australia, applies only to supplies under Part VII of the National Health Act 1953, and excludes benefits or circumstances already governed by other special arrangements (s6). It explicitly preserves state and territory restrictions on Schedule 8 drugs (s8(3) note), so prescribers and suppliers must account for dual compliance layers.

The instrument imposes discrete duties on prescribers, approved suppliers and software vendors, and it creates rights for agencies to request records.

Duties on PBS prescribers

• Prescription creation duty. A PBS prescriber may only prescribe under this Special Arrangement by creating an electronic medication order inside an electronic medication chart in accordance with section 41 of the Regulations as modified by the instrument (s8(1)). That incorporates the requirement that the electronic medication chart contains the standard fields set by the Approval Instrument (s4 definition).

• Conformance and location duty. A prescription may only be made for a person receiving residential care at an approved residential care home and only using a transitional conformant electronic medication chart system (s8(2)(a)-(b)).

• Electronic approval duty. The prescriber must electronically approve the prescription in the electronic medication chart system (s8(4)).

• Authority details duty. Where an authority approval number or streamlined authority code applies to the prescription, the electronic medication order must contain it (s8(5)).

• Paper form non‑requirement. The prescriber is not required to provide a paper‑based prescription in addition to the electronic order (s8(7)), subject to other legal obligations (for example, state requirements for certain drugs).

Duties on approved suppliers

• Access and supply condition. An approved supplier may supply a pharmaceutical benefit under the arrangement only if the prescription was created using a transitional conformant system and was made available to the supplier before supply (s9(1)).

• Verification and recording duty. The supplier must verify in the electronic medication order that the benefit has been supplied and the date of supply; this replicates the effect of section 45 of the Regulations as modified by the instrument (s9(2)(b)(i)). The instrument treats references to medication chart prescriptions as references to electronic medication orders for purposes of sections 45, 47 and 51 of the Regulations, subject to the instrument’s modifications (s9(2)(a), (c)).

• Immediate supply marking substitute. Where section 51 of the Regulations otherwise requires writing “immediate supply necessary” on the prescription, the instrument treats that as including those words in the electronic medication order (s9(2)(c)).

• Record creation and retention duty. For each supply based on an electronic medication order for which a claim is made under s99AAA of the Act, the approved supplier must prepare an electronic pharmacy record and retain it for not less than two years after the day of supply (s10(5)). The record must contain all information required by Schedule 1 to the Rules for a CTS claim (s10(6)).

• Submission duty on notice. If Chief Executive Medicare notifies the approved supplier in writing, the supplier must submit copies of electronic medication orders or electronic pharmacy records to the Department administered by the Minister who administers the Human Services (Centrelink) Act 1997 (s10(4), (7)). Notices may apply to one or more orders/records (s10(8)).

Duties on software vendors and system operators

• Conformance and listing. To be used for prescribing under this Special Arrangement, the vendor’s system must be listed on the Transitional eNRMC Conformance Register as at 1 October 2025; the definition of transitional conformant electronic medication chart system depends on that snapshot registration (s4).

• Functional constraints. The system must be accessible by approved suppliers for viewing and annotating chart data and must not allow charts or orders created using the system to be sent to the national prescription delivery service (s4).

Rights and agency powers

• Chief Executive Medicare notice power. The Chief Executive Medicare has the right to notify suppliers in writing that copies of electronic medication orders or electronic pharmacy records are required to be submitted to the Department specified (s10(4), (7)). Notices can cover multiple orders/records (s10(8)).

• Claim entitlements under Part VII. For supplies made in accordance with the Special Arrangement, the supplies are treated as supplied under Part VII of the Act and provisions of Part VII, the Regulations and other instruments apply subject to the Special Arrangement (s7(1)-(2)). This preserves suppliers’ entitlement to make claims under s99AAA of the Act, subject to the instrument’s modifications to the Rules (s10(1)).

Special coding concession

• Fred IT Group exception. Where a supply uses software made available by Fred IT Group Pty Ltd and the supply meets one of two conditions,either an authority to write the prescription was required from Chief Executive Medicare under a named Listing Instrument, or the drug is listed in Schedule 8 of the Poisons Standard,the Patient Category details for a patient in the Residential aged care facility patient (medication chart prescription) category for item 25 of the Rules’ Schedule 1 table are 0 (zero) (s10(2)-(3)). That is an express, instrument‑level operational change to how a supplier must record a particular claim item for those circumstances.

Limits, exceptions and preserved legal obligations

• Scope boundaries. The Special Arrangement does not apply to pharmaceutical benefits that can only be supplied under another special arrangement or in circumstances prescribed by another special arrangement (s6(2)-(3)).

• State/territory regulatory overlay for controlled drugs. PBS prescribers and approved suppliers remain subject to state and territory controls on prescribing and dispensing Schedule 8 drugs, even though paragraph 41(2)(g) of the Regulations is excluded for electronic medication orders in the chart system (s8(3) note).

• Transitional preservation. Section 9 and 10 of the former Special Arrangement continue to apply to transitional prescriptions and claims as if the former arrangement had not been repealed (ss12-13).

The instrument therefore imposes concrete operational duties with explicit record and verification obligations, binds software vendors to register or conform by the transitional register snapshot, establishes a discrete right for Chief Executive Medicare to demand records, and creates a targeted claim coding effect for a named private software supplier.

The instrument itself does not specify new criminal sanctions, civil penalties or enforcement mechanisms in express terms. Instead, enforcement and compliance operate through three channels that the instrument establishes or modifies: (1) adaptation of existing regulatory provisions in Part VII and the Regulations to the electronic medication order context, (2) record submission powers exercisable by Chief Executive Medicare, and (3) the usual claim and payment controls that flow from the Rules and s99AAA claims regime.

Application and reliance on existing Part VII enforcement regimes

• Part VII and the Regulations continue to apply subject to the Special Arrangement (s7(1)-(2)). That means any civil or administrative penalties, disallowance, payment withholding or other compliance mechanisms contained in the National Health Act 1953 and its Regulations for improper claims, false statements or non‑compliance with Part VII will continue to be available, but their operation in the context of electronic medication orders will be subject to the instrument’s specific modifications. The instrument does not itself reproduce Part VII enforcement provisions; investigators and administrators will rely on the Act and Regulations for enforcement.

Record submission and audit power

• Chief Executive Medicare notice power. Chief Executive Medicare may notify approved suppliers in writing to submit copies of electronic medication orders or electronic pharmacy records to a specified Department (s10(4), (7)). The instrument makes no express statement about penalties for failure to comply with such notices, but failure to comply may engage existing Part VII compliance provisions or conditions attached to the approved supplier status under the Act and Regulations. The instrument also permits notices to apply to one or more orders or records (s10(8)), enabling bulk or targeted requests.

Verification obligations and prescriptive recording

• Verification obligations. The instrument requires that, as a modification of s45, approved suppliers verify in the electronic medication order that the pharmaceutical benefit has been supplied and the date of supply (s9(2)(b)(i)). That creates a specific evidentiary requirement for suppliers when questioned about whether supply occurred. Non‑compliance with these recordation obligations will intersect with general rules about claims, including potential non‑payment or recovery of amounts, under Part VII and the Rules.

Implied enforcement by claims process

• Claims control. The instrument modifies the Rules and prescribes the form of Patient Category details in certain circumstances (s10(1)-(3)). The claims processing and payment machinery will enforce those requirements de facto: incorrect coding, failure to include required authority numbers in the electronic medication order, or missing electronic pharmacy records may lead to rejected claims, requests for further documentation or payment recovery. The instrument does not itself authorise additional monetary penalties.

Absence of instrument‑specific sanctions

• No new criminal or civil penalties specified. The Special Arrangement does not create new offences, pecuniary penalties or infringement notices within its text. Any sanction for breach of the duties it imposes must therefore be sought in the Act, the Regulations, the Rules, or in the existing administrative regime governing approved suppliers and PBS claims. Practitioners should therefore examine the Act and the Regulations for the analytical next step if compliance failures are discovered.

Operational enforcement risks

• Audit and disclosure. The Chief Executive Medicare notice power to require submission of orders or records (s10(4), (7)) creates a practical audit mechanism. Approved suppliers must be prepared to locate and produce electronic medication orders and pharmacy records within the context of that notice. The instrument’s record retention requirement of not less than two years (s10(5)) sets a minimum retention period that supports administrative audits.

• Delegated application of regulations. Because the instrument treats an electronic medication order as a medication chart prescription for purposes of much of the Regulations, regulatory rules that attach to medication chart prescriptions (other than s61, as carved out in s8(6)) will be available for enforcement. The instrument modifies some of those obligations but makes the Regulations the underlying enforcement architecture.

In short, the Special Arrangement enforces compliance mainly by integrating its requirements into the existing claim, regulation and audit architecture under Part VII, using the Chief Executive Medicare’s notice power to obtain documentary evidence and relying on Part VII/Regulations/Rules to apply consequences for non‑compliance. The instrument itself does not set out bespoke penalties.

The instrument explicitly ties itself into several other statutory and administrative instruments and leaves certain other legal regimes intact.

Direct statutory interactions

• National Health Act 1953, Part VII. The instrument is made under subsections 100(1) and 100(2) of the National Health Act 1953 (s3). It applies to pharmaceutical benefits supplied under Part VII and states that each supply under the Special Arrangement is supplied under Part VII (s7(1)). It also states that provisions of Part VII, the Regulations and other instruments apply subject to this Special Arrangement (s7(2)). Practically, this means that the instrument modifies the application of existing Part VII law rather than replacing it.

• National Health (Pharmaceutical Benefits) Regulations 2017. The instrument modifies the operation of specific regulatory provisions relating to medication chart prescriptions and supply (s8(3), s8(6), s9(2)). It excludes paragraphs 41(2)(c) and 41(2)(g) from applying to electronic medication orders created within an electronic medication chart (s8(3)). The instrument then treats an electronic medication order as a medication chart prescription for the purposes of the Regulations (except s61) and modifies sections 45, 47 and 51 in the supply context (s8(6), s9(2)).

• National Health (Supply of Pharmaceutical Benefits,Under Copayment Data and Claims for Payment) Rules 2022. The instrument allows approved suppliers to make claims in accordance with the Rules as modified by the instrument (s10(1)). It changes how item 25, and the Patient Category details for Residential aged care facility patient (medication chart prescription), are to be populated under certain software conditions (s10(2)-(3)), and ties required information for CTS claims to the content of the electronic pharmacy record (s10(6)).

Cross‑references to other Commonwealth instruments

• National Residential Medication Charts Approval Instrument 2025. The instrument imports the standard fields required for an electronic medication chart from Schedule 1 to the National Health (Pharmaceutical Benefits) National Residential Medication Charts Approval Instrument 2025, as in force on 1 November 2025 (s4 definition of electronic medication chart). The instrument therefore depends on the Approval Instrument for the specific data elements that must appear on an electronic medication chart.

• Transitional eNRMC Conformance Register and Australian Digital Health Agency. The instrument defines a transitional conformant electronic medication chart system by reference to the Transitional eNRMC Conformance Register maintained by the Australian Digital Health Agency as it exists on 1 October 2025 (s4). The register’s contents, as of that date, determine which vendor systems may be used.

• Poisons Standard and state/territory law. The instrument notes that exclusion of paragraph 41(2)(g) enables prescriptions using electronic medication orders to be made under this arrangement for pharmaceutical benefits that are referred to in Schedule 8 of the Poisons Standard; however, PBS prescribers and approved suppliers remain subject to any restrictions on prescribing or dispensing Schedule 8 drugs in applicable state or territory legislation (s8(3) note). That preserves the overlapping jurisdictional control over controlled drugs.

• Human Services (Centrelink) Act 1997 administration. Chief Executive Medicare may require submission of documents to the Department administered by the Minister who administers the Human Services (Centrelink) Act 1997 (s10(4), (7)). This links the Special Arrangement’s audit flow to an existing Departmental recipient.

Transitional and historic instruments

• Former Special Arrangement (2018 trial). The instrument expressly preserves the continued operation of section 9 and section 10 of the former Special Arrangement in relation to transitional prescriptions and claims made before the transition time (ss11-13). That ensures continuity for supplies and claims started under the earlier trial.

• Aged Care Act 1997 / Aged Care Act 2024. The instrument references the Aged Care Act 2024 when defining approved residential care home (s4). It also creates a temporary bridge between the old Aged Care Act 1997 definitions and the new Aged Care Act 2024 definitions for prescriptions written in a specified interregnum between 1 November 2025 and registration of the named Amendment Special Arrangement (s14).

Operational and interoperability interactions

• National prescription delivery service. The instrument requires that eligible electronic medication chart systems must not allow charts or electronic medication orders created using the system to be sent to the national prescription delivery service (s4). That creates a direct interoperability constraint: systems that rely on the national prescription delivery service as a transmission pathway for e‑prescriptions cannot be used for these eNRMC prescriptions. The instrument does not amend the rules governing the national prescription delivery service; it simply forbids its use for these charts.

• Vendor and supplier markets. The instrument’s use of a limited snapshot of a conformance register (as at 1 October 2025) as the definitional test for conformance, and the naming of a specific vendor for a claim coding outcome (s10(3)), create concrete interactions between this instrument and the commercial vendor market for residential medication software. These are instrument design choices that allocate legal eligibility to systems listed by a named administrative body and create a discrete claim coding effect tied to a named vendor.

In sum, the instrument integrates into the existing Commonwealth pharmaceutical benefits scheme, modifies and reinterprets specific parts of the Regulations and the Rules for an electronic medication chart context, preserves other legal overlays such as state controls on Schedule 8 drugs, and uses administrative registers and named instruments to define technical and commercial eligibility. Legal compliance therefore requires attention both to this instrument and to the connected Regulations, Rules, Approval Instrument and the content of the transitional conformance register.

The instrument itself sets out limited internal amendment metadata and contemplates the effect of Schedules in changing other instruments, but in the text provided there is no record of subsequent amendments to PB 119 of 2025. The relevant points from the instrument are:

• Identification and commencement. The instrument is titled the National Health (Transitional Electronic National Residential Medication Chart) Special Arrangement 2025 and may also be cited as PB 119 of 2025 (s1). The whole of the instrument commences on 1 October 2025 (s2 and commencement table). The instrument’s commencement table includes a note that the table relates only to the provisions of this instrument as originally made, and that it will not be amended to deal with later amendments (s2(1) note).

• Schedules to this instrument. Section 5 provides that each instrument specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the relevant Schedule, and that any other item in a Schedule takes effect according to its terms (s5). The instrument therefore contemplates that its Schedules may amend or repeal other instruments, but the Schedules themselves are not provided in the text under review. Practitioners must therefore check the published instrument and its Schedules on the Federal Register of Legislation for any amendments made at instrument creation time.

• References to instruments as in force on specified dates. The instrument imports the content of the National Residential Medication Charts Approval Instrument 2025 as in force on 1 November 2025 for standard fields of the electronic medication chart (s4 definition), and it uses the Transitional eNRMC Conformance Register as existing on 1 October 2025 for the conformance definition (s4). That means the instrument fixes the content of those external instruments/registries at specific dates for the purpose of defining obligations within this Special Arrangement. Future updates to the Approval Instrument or the Register after those dates will not automatically alter the substance of this instrument’s definitions as drafted.

• Transitional carryover of the former Special Arrangement. Sections 11 to 13 establish transitional definitions and preserve certain operation of the Former Special Arrangement (the National Health (Electronic National Residential Medication Chart Trial) Special Arrangement 2018) for transitional prescriptions and claims. Those transitional provisions themselves are part of the instrument’s original text and represent an intra‑instrument historical continuity device, but the instrument does not otherwise provide an amendment timeline.

• No recorded amendments in the source. The version of the instrument provided contains no annotations of subsequent amendments, revocations or replacement instruments beyond those contained as original text. To ascertain post‑commencement amendments, practitioners must consult the Federal Register of Legislation or legislative instruments registers for amendment history following registration.

In practice, the instrument’s reliance on other instruments as at fixed dates creates a frozen‑in time link that reduces some amendment ambiguity but requires cross‑checking of the relevant Approval Instrument and register snapshots for operational compliance. The Schedules to this Special Arrangement may have amended other instruments at the time of making, but those Schedules were not provided here; check the official published version for schedule content and any consequential amendments.

The instrument text provided contains no record of litigation. It does not reference any judicial decisions, declaratory judgments, or administrative tribunal determinations. It names a former Special Arrangement (the 2018 trial) and preserves certain of its provisions for transitional prescriptions (ss11-13), but it does not reference any court or tribunal consideration of that prior instrument.

Consequently, within the source material there is no litigation history to summarise. Practitioners seeking litigation precedent or challenges to this Special Arrangement should search court databases and the Federal Register of Legislation for any judicial proceedings commenced after the instrument’s registration date or any legal challenges to the constituent Approval Instrument, the transitional conformance register, or the former Special Arrangement.

Absent any litigation record in the instrument itself, the immediate compliance and dispute risks are administrative or contractual rather than judicial. Potential grounds for litigation that might arise in future include disputes about (1) whether a system is properly listed on the Transitional eNRMC Conformance Register as of the relevant snapshot date, (2) whether a particular electronic medication order was “made available” to an approved supplier before supply, (3) whether a Chief Executive Medicare notice was properly issued under s10(4) or (7), and (4) questions about whether the special coding treatment in s10(2)-(3) should have been applied to a particular claim. Those are speculative litigation pathways; the instrument itself does not record any such cases.

Practitioners should monitor administrative reviews and judicial reviews relating to the Australian Digital Health Agency’s register management, the Approval Instrument, the Secretary/Chief Executive Medicare decisions that authorise or require submissions, and any disputes arising in the claims processing context under the Rules and Part VII of the Act.

This instrument contains several operational and legal traps for prescribers, suppliers, vendors and residential care providers. The following are concrete pitfalls that arise directly from the text.

1. Conformance snapshot dependence. The instrument defines a transitional conformant electronic medication chart system by reference to the Transitional eNRMC Conformance Register as it exists on 1 October 2025 (s4). That is a date‑bound snapshot. If a vendor is not listed on that register as at that date, the vendor’s system cannot be used to create prescriptions under this Special Arrangement even if the vendor later becomes conformant. The instrument therefore achieves a “freeze frame” eligibility that can unexpectedly exclude newer systems. Vendors and providers must confirm the register snapshot status.

2. Prohibition on use of the national prescription delivery service. The instrument requires an eligible system not to allow electronic medication charts or orders created using the system to be sent to the national prescription delivery service (s4). Vendors and pharmacies that rely on that service for transmission will be unable to use it for these charts. That may require workflow changes, additional integration costs, or duplicate processes to support supplies. The instrument does not define an alternative transmission path; the practical effect is that approved suppliers must access the chart system directly.

3. Ambiguity in “made available”. Section 9(1) conditions supply on the prescription having been “made available to the approved supplier, before the pharmaceutical benefit is supplied” (s9(1)). The instrument does not define the legal meaning of “made available” (for example, what constitutes sufficient notice, what timestamp prevails if system clocks differ, whether the supplier needs an affirmative notification). This creates operational uncertainty that could lead to rejected claims or administrative queries if the supplier supplies a medicine before demonstrable system access is shown.

4. Limited claim coding concession tied to a named vendor. Section 10(3) requires Patient Category details to be zero in item 25 when supplies use software made available by Fred IT Group Pty Ltd in specified circumstances (s10(2)-(3)). The instrument explicitly names a private entity and ties a claim coding outcome to its software, which is an unusual instrument‑level commercial specificity. Approved suppliers using other vendors will not benefit from that exact coding outcome in those specific circumstances; suppliers and payers need to check whether their software triggers the same claim outcome.

5. Exclusion of parts of s41 of the Regulations. The instrument removes the application of paragraphs 41(2)(c) and 41(2)(g) of the Regulations for creation of electronic medication orders (s8(3)). The instrument notes that excluding 41(2)(g) enables electronic prescription of Schedule 8 drugs in the chart system but expressly preserves state and territory controls (s8(3) note). Practitioners cannot assume that the full regulatory control environment is changed; they must check state laws on controlled drugs and the contained effect of the excluded paragraphs to understand operational consequences.

6. Record content required by another instrument. Electronic medication charts must contain the standard fields in Schedule 1 of the Approval Instrument 2025 as in force on 1 November 2025 (s4), and electronic pharmacy records must contain all information required by Schedule 1 to the Rules for a CTS claim (s10(6)). The instrument therefore imports field and data content requirements from two separate instruments that are not reproduced here. Compliance requires cross‑reference to those Schedules.

7. Retention period alignment. The instrument imposes a two‑year retention minimum for electronic pharmacy records (s10(5)). Practitioners should check whether other record retention obligations under state law, professional regulation or Medicare conditions are longer, because the instrument sets a floor not a ceiling. Misalignment across retention rules could cause conflicting obligations.

8. Transitional complexity with former Special Arrangement. The instrument preserves certain operations of the former Special Arrangement for transitional prescriptions and claims (ss11-13). Providers must identify which prescriptions are transitional (those made before the transition time of 1 October 2025 and made under the former arrangement modified by its section 7) and which are governed by the new instrument to avoid incorrect reliance on older processes.

9. Temporary bridge for aged care definitions. Section 14 expands the definition of person receiving residential care to include persons under the old Aged Care Act 1997 definitions for prescriptions written in a time window after 1 November 2025 and before registration of a named Amendment Special Arrangement (s14). Care must be taken to determine whether a prescription falls within that interregnum period and to apply the correct definition.

10. Chief Executive Medicare notice power. The instrument allows Chief Executive Medicare to require production of electronic medication orders and pharmacy records (s10(4), (7)-(8)). Approved suppliers should have ready search, export and production capability; suppliers without efficient records production may face operational and compliance strain when responding to notices.

11. No new penalties specified. The instrument does not itself specify new penalties or enforcement mechanisms. Enforcement will operate through the Act, Regulations and the claims process. That means consequences for non‑compliance will be determined by existing Part VII mechanisms rather than by new, instrument‑specific fines; suppliers must map this instrument’s duties onto the broader compliance regime.

Each of these “gotchas” is a direct consequence of the instrument text. Effective operational risk management requires cross‑checking the Approval Instrument, the Transitional eNRMC Conformance Register as at the required snapshot dates, the Rules’ Schedule 1, and any relevant state and territory controls.

This section sets out concrete, actionable steps for each of the principal parties to bring their systems and processes into alignment with the Special Arrangement. All steps are traceable to specific instrument provisions cited.

For software vendors and system operators

• Verify listing on the Transitional eNRMC Conformance Register as at 1 October 2025. If your system is to be used for prescriptions under the Special Arrangement, ensure it is listed on the Transitional eNRMC Conformance Register maintained by the Australian Digital Health Agency as it existed on 1 October 2025 (s4). If not listed on that snapshot, the system cannot be used for these prescriptions.

• Implement required chart fields. Ensure the electronic medication chart includes all standard fields set out in Schedule 1 to the National Residential Medication Charts Approval Instrument 2025 as in force on 1 November 2025 (s4 definition). Cross‑check the Approval Instrument’s Schedule 1 and update data models and forms accordingly.

• Restrict transmission to exclude the national prescription delivery service. Architect the system so that electronic medication charts and electronic medication orders created using the system cannot be sent to the national prescription delivery service (s4). Where other parts of your system use that service, provide clear, auditable separation of workflows that ensures charts created for this Special Arrangement cannot be transmitted via the national service.

• Provide supplier access and annotation capability. The system must be accessible by approved suppliers for the purpose of viewing and annotating electronic medication charts (s4). Implement secure role‑based access controls, logging and annotation features that permit pharmacists to verify supply and record dates in the order (s9(2)(b)(i)).

• Support authority numbers and streamlined authority codes. Ensure the electronic medication order data model includes fields for authority approval numbers and streamlined authority codes and that these fields are enforced when applicable (s8(5)).

• Provide export and audit facilities. Suppliers may be required to submit copies of electronic medication orders or pharmacy records to a Department when notified by Chief Executive Medicare (s10(4), (7)-(8)). Provide reliable export, PDF and structured data formats with time stamps and audit trails.

For PBS prescribers

• Use a transitional conformant system and restrict to eligible patients. Only create prescriptions within an electronic medication chart system that is transitional conformant and only for patients receiving residential care at an approved residential care home (s8(1)-(2)). If prescribing during the interregnum specified in s14, confirm whether the patient falls within the old Aged Care Act definition if relevant.

• Electronically approve and include authority details. Electronically approve the electronic medication order in the system (s8(4)). If an authority number or streamlined authority code is required for the prescription, ensure it is included in the order (s8(5)).

• Do not assume paper supplement is needed. The prescriber is not required to supply a paper prescription in addition to the electronic order (s8(7)), but check state/territory requirements for Schedule 8 drugs where paper or additional forms may still be required (s8(3) note).

• Keep local audit evidence. Retain evidence of electronic approval, and where relevant, ensure systems capture authenticated user IDs, dates and times to support potential audit requests from Chief Executive Medicare.

For approved suppliers (pharmacies)

• Verify access to the chart system before supplying. Before supplying a pharmaceutical benefit under the arrangement, confirm that the prescription was created using a transitional conformant system and that the prescription has been made available to you before supply (s9(1)). Given the instrument’s silence on the precise test for “made available”, implement a clear operational rule,for example, require an explicit electronic notification, a visible timestamped order in the chart system, or a signed electronic assent,so supply teams have a consistent trigger to proceed.

• Record supply in the electronic medication order. Record verification that the pharmaceutical benefit has been supplied and the date of supply in the electronic medication order itself, consistent with s45 as modified by the instrument (s9(2)(b)(i)). Ensure the annotation is auditable and persists in the electronic medication order.

• Implement “immediate supply necessary” handling. Where immediate supply marking is relevant, include the words “immediate supply necessary” in the electronic medication order as the instrument substitutes that action for the paper procedure (s9(2)(c)).

• Prepare and retain electronic pharmacy records. For each supply based on an electronic medication order for which you make a s99AAA claim, prepare an electronic pharmacy record and retain it for at least two years (s10(5)). Ensure the record contains all information required by Schedule 1 to the Rules for a CTS claim (s10(6)). Cross‑reference Schedule 1 to the Rules to confirm data elements and formats.

• Be ready to respond to Chief Executive Medicare notices. Implement procedures to locate, export and transmit copies of electronic medication orders and electronic pharmacy records when notified in writing by Chief Executive Medicare (s10(4), (7)). Ensure you can produce multiple orders/records if the notice so requests (s10(8)).

• Check claim coding when using Fred IT Group software. If you use software made available by Fred IT Group and the supply falls within s10(3)(a)-(b), record Patient Category details for item 25 as 0 (zero) as required (s10(2)-(3)). Confirm with your claim processing software that the correct coding is applied.

For approved residential care homes and administrators

• Provide and support approved chart systems. Ensure that the electronic medication chart system used for residents is transitional conformant as required (s8(2)(b), s4). If you provide devices or network access for prescribers and suppliers to use the vendor system, ensure secure connectivity, authentication and staff training.

• Coordinate prescribers and suppliers. Implement workflows that ensure prescribers create and electronically approve electronic medication orders prior to supply, and that approved suppliers can view and annotate those orders before supply occurs (s8(4), s9(1), s9(2)(b)(i)).

• Retain records and support audits. Although the retention obligation sits with the approved supplier, residential care homes should maintain their own audit trails and integration logs showing when orders were created, approved and made available to suppliers to mitigate disputes about timing and “made available” (s9(1)).

Cross‑cutting compliance actions

• Map all external instruments. Cross‑check Schedule 1 to the Approval Instrument 2025, Schedule 1 to the Rules, the Transitional eNRMC Conformance Register snapshot (1 October 2025) and any Schedules to this Special Arrangement published at instrument registration to ensure you meet exact field and data requirements (s4, s10(6), s5).

• Document procedures and training. Document internal policies for the exact triggers that mean a prescription is “made available”, who may annotate orders, how verification is recorded and how to respond to Chief Executive Medicare notices. Train prescribers, pharmacy staff and nursing staff in those policies.

• Integrate audit trails and export formats. Implement exportable, stamped records and efficient search tools so that when notified by Chief Executive Medicare, you can promptly deliver requested electronic medication orders or pharmacy records (s10(4), (7)). Preserve metadata such as user IDs, timestamps and change histories.

• Reconcile state and territory requirements. For Schedule 8 drugs particularly, reconcile the electronic medication order workflows with applicable state and territory law on controlled substances and any professional practice rules that may require additional documentation beyond the instrument’s electronic order (s8(3) note).

• Monitor Part VII claims processes. Ensure claim submission integrates the instrument’s claim modifications, notably the item 25 Patient Category adjustment in specified Fred IT Group cases (s10(2)-(3)), and that the supplier’s claims process will accept the electronic pharmacy record as supporting documentation.

• Keep an eye on updates and publication sources. Because the instrument relies on external Approval Instruments and registers at specific dates, practitioners should obtain the published instrument and linked Schedules from the Federal Register of Legislation and maintain copies of the register snapshot and Approval Instrument versions used to determine compliance.

These compliance steps convert the instrument’s textual duties into operational procedures. The two principal risks to manage are (1) technical eligibility of vendor systems based on the register snapshot and the system’s functional constraints, and (2) documentary traceability for the “made available” and verification requirements that determine whether a supply is lawful under the Special Arrangement.